Mitochondria–directed antioxidants (MnSOD mimetics) and classic mitochondrial antioxidants (coenzyme Q10 or CoQ10, α-lipoic acid) have a substantial preclinical and some clinical track record in limiting mitochondrial oxidative injury and improving bioenergetics in mitochondrial disease contexts; these could be repurposed or trialed as adjuncts in WD to reduce ROS–mediated respiratory chain damage while chelation therapies lower copper load. Here, SOD2 is linked to inborn mitochondrial metabolism disorder.